Xlife Sciences AG (SIX: XLS) announced on December 23, 2025, that its Board of Directors has resolved to move from the SIX Sparks segment to the main segment of the SIX Swiss Exchange. This strategic step is intended to increase the company's visibility, improve liquidity, and strengthen recognition in the capital markets. Following a preliminary legal review, Xlife Sciences meets all requirements and will promptly submit the corresponding application to SIX, with the segment change planned for the first quarter of 2026.
The transition to the main segment represents a significant milestone for Xlife Sciences, which operates as an incubator and accelerator for promising research projects in life sciences. The company focuses on developing and commercializing technologies from universities and research institutions, addressing high unmet medical needs. By moving to the main segment, Xlife Sciences expects to attract a broader base of institutional investors and enhance the tradability of its shares.
In addition to the segment change, Xlife Sciences is investing in market-making and research activities to further boost visibility and liquidity. Oliver R. Baumann, CEO of Xlife Sciences AG, stated, "Transitioning to the main segment of SIX is the next logical step for Xlife Sciences: it increases visibility, improves the liquidity of our shares, and provides additional access to institutional investors. In parallel, we are intensifying efforts in market-making and research coverage to further enhance the attractiveness for existing and new shareholders."
The company's financial calendar includes the Annual Report 2025 on April 28, 2026, the Annual Shareholders Meeting 2026 on June 26, 2026, and the Half-Year Report 2026 on September 24, 2026. Xlife Sciences AG is headquartered in Zurich, Switzerland, and its shares are currently listed on the SIX Swiss Exchange under the ticker XLS. More information is available on the company's website at https://www.xlifesciences.ch.
The move to the main segment underscores Xlife Sciences' strategic development and commitment to providing solutions for high unmet medical needs and better quality of life. The company carefully selects projects in technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health, taking them to the next stage of development and participating in their subsequent performance.
